Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

被引：0
|
作者：
Jeeyun Lee
Kyung Hae Jung
Young Suk Park
Joong Bae Ahn
Sang Jun Shin
Seock-Ah Im
Do Youn Oh
Dong Bok Shin
Tae Won Kim
Namsu Lee
Jae Ho Byun
Yong Sang Hong
Joon Oh Park
Se Hoon Park
Ho Yeong Lim
Won Ki Kang
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Research Institute and Hospital,Oncology, Department of Medicine, Samsung Medical Center
[3] Yonsei University College of Medicine,Center for Colorectal Cancer, National Cancer Center
[4] Seoul National University College of Medicine,Department of Internal Medicine
[5] Gachon University Gil Medical Center,Department of Internal Medicine
[6] University of Ulsan College of Medicine,Division of Hematology and Oncology, Department of Internal Medicine
[7] Soon Chun Hyang University Hospital,Division of Oncology, Department of Medicine, Asan Medical Center
[8] The Catholic University of Korea,Division of Hematology
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 64卷
关键词：
Statin; Simvastatin; Irinotecan; Cetuximab; Lovastatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：657 / 663
页数：6
相关论文
共 50 条
  • [11] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Juan José Reina
    Jorge Aparicio
    Javier Salvador
    José María Puerto Pica
    Antonio Rueda
    Antonio Lorenzo
    Carlos González de la Puente
    Pablo Borrega
    José Andrés Moreno-Nogueira
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 339 - 345
  • [12] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Reina, JJ
    Aparicio, J
    Salvador, J
    Pica, JMP
    Rueda, A
    Lorenzo, A
    de la Puente, CG
    Borrega, P
    Moreno-Nogueira, JA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (04) : 339 - 345
  • [13] Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer
    Ji, SH
    Park, YS
    Lee, J
    Lim, DH
    Park, BB
    Park, KW
    Kang, JH
    Lee, SH
    Park, JO
    Kim, K
    Kim, WS
    Jung, CW
    Im, YH
    Kang, WK
    Park, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) : 214 - 217
  • [14] First line polichemotherapy (PCT) with irinotecan plus leucovorin plus 5-fluorouracil (FOLFIRI) and bevacizumab in patients (Pts) with metastatic colorectal cancer (MCRC): A phase II study in our institution
    Roda, G.
    Nonnis, D. Carta A.
    Galmozzi, A.
    Nastasi, G.
    Cotroneo, G.
    ANNALS OF ONCOLOGY, 2007, 18 : 8 - 8
  • [15] A phase II study of irinotecan, oxaliplatin, 5-fluorouracil, leucovorin (FOLFOXIRI) as a first-line chemotherapy in metastatic gastric cancer.
    Lee, J.
    Kang, W.
    Lee, S.
    Kwon, J.
    Kim, H.
    Lee, H.
    Lim, H.
    Park, J.
    Park, Y.
    Park, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 197S - 197S
  • [16] A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer
    Cascinu, S
    Silva, RR
    Labianca, R
    Barni, S
    Mattioli, R
    Martignoni, G
    Frontini, L
    Gasparini, G
    Catalano, V
    Baldelli, AM
    Giuliodori, L
    Agostinelli, R
    Catalano, G
    ANNALS OF ONCOLOGY, 1999, 10 (08) : 985 - 987
  • [17] Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer
    Berlin, Jordan
    Posey, James
    Tchekmedyian, Simon
    Hu, Eddie
    Chan, David
    Malik, Imtiaz
    Yang, Liqiang
    Amado, Rafael G.
    Hecht, J. Randolph
    CLINICAL COLORECTAL CANCER, 2007, 6 (06) : 427 - 432
  • [18] 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) plua bevacizumab in patients with metastatic colorectal cancer: Preliminary results of a multicenter phase II trial
    Cordio, S.
    Condorelli, S.
    Rosati, G.
    Soto-Parra, H.
    Caputo, G.
    Rampello, E.
    Salice, P.
    Rimassa, L.
    Pumo, V
    Manzione, L.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 99 - 99
  • [19] Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
    Kalofonos, HP
    Aravantinos, G
    Kosmidis, P
    Papakostas, P
    Economopoulos, T
    Dimopoulos, M
    Skarlos, D
    Bamias, A
    Pectasides, D
    Chalkidou, S
    Karina, M
    Koutras, A
    Samantas, E
    Bacoyiannis, C
    Samelis, GF
    Basdanis, G
    Kalfarentzos, F
    Fountzilas, G
    ANNALS OF ONCOLOGY, 2005, 16 (06) : 869 - 877
  • [20] Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study
    Aranda, E.
    Valladares, M.
    Martinez-Villacampa, M.
    Benavides, M.
    Gomez, A.
    Massutti, B.
    Marcuello, E.
    Constenla, M.
    Camara, J. C.
    Carrato, A.
    Duenas, R.
    Reboredo, M.
    Navarro, M.
    Diaz-Rubio, E.
    ANNALS OF ONCOLOGY, 2009, 20 (02) : 251 - 257
12345